Drugs / ABO1009-DP
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05433194 | Aug → Sep 2022 | COVID-19 | Suzhou Abogen Biosciences Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05434585 | Jul → Oct 2022 | COVID-19 | Suzhou Abogen Biosciences Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABO1009-DP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05434585 ↗ |
| Modality | Messenger RNA (mRNA) | “SARS-CoV-2 Variant (Omicron) mRNA Vaccine (ABO1009-DP)” NCT05433194 ↗ |
| Route | Intramuscular | “Intramuscularly injecting 15 μg of ABO1009-DP into lateral deltoid region of the upper arm of subjects on D0.” NCT05433194 ↗ |